BR112022013143A2 - Tratamento de combinação contra câncer usando um antagonista de pd-1, um antagonista de ilt4 e lenvatinibe ou sais dos mesmos - Google Patents

Tratamento de combinação contra câncer usando um antagonista de pd-1, um antagonista de ilt4 e lenvatinibe ou sais dos mesmos

Info

Publication number
BR112022013143A2
BR112022013143A2 BR112022013143A BR112022013143A BR112022013143A2 BR 112022013143 A2 BR112022013143 A2 BR 112022013143A2 BR 112022013143 A BR112022013143 A BR 112022013143A BR 112022013143 A BR112022013143 A BR 112022013143A BR 112022013143 A2 BR112022013143 A2 BR 112022013143A2
Authority
BR
Brazil
Prior art keywords
antagonist
cancer
lenvatinib
ilt4
salts
Prior art date
Application number
BR112022013143A
Other languages
English (en)
Inventor
A Altura Rachel
E Brandish Philip
Fleury PERINI Rodolfo
Original Assignee
Merck Sharp & Dohme Llc
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc, Eisai R&D Man Co Ltd filed Critical Merck Sharp & Dohme Llc
Publication of BR112022013143A2 publication Critical patent/BR112022013143A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

TRATAMENTO DE COMBINAÇÃO CONTRA CÂNCER USANDO UM ANTAGONISTA DE PD-1, UM ANTAGONISTA DE ILT4 E LENVATINIBE OU SAIS DOS MESMOS. São fornecidos na presente invenção métodos para tratar câncer (por exemplo, RCC), que compreendem administrar a um paciente humano em necessidade do mesmo: (a) um antagonista de PD-1; (b) um antagonista de ILT4; e (c) lenvatinibe representado pela Fórmula (I): ou um sal farmaceuticamente aceitável dos mesmos. Também são fornecidos kits contendo tais agentes e usos de combinações terapêuticas de tais agentes para o tratamento de câncer.
BR112022013143A 2020-01-02 2020-12-18 Tratamento de combinação contra câncer usando um antagonista de pd-1, um antagonista de ilt4 e lenvatinibe ou sais dos mesmos BR112022013143A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062956469P 2020-01-02 2020-01-02
PCT/US2020/065799 WO2021138079A1 (en) 2020-01-02 2020-12-18 Combination cancer treatment using a pd-1 antagonist, an ilt4 antagonist, and lenvatinib or salts thereof.

Publications (1)

Publication Number Publication Date
BR112022013143A2 true BR112022013143A2 (pt) 2022-09-20

Family

ID=76687248

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022013143A BR112022013143A2 (pt) 2020-01-02 2020-12-18 Tratamento de combinação contra câncer usando um antagonista de pd-1, um antagonista de ilt4 e lenvatinibe ou sais dos mesmos

Country Status (10)

Country Link
US (1) US20230058779A1 (pt)
EP (1) EP4084794A4 (pt)
JP (1) JP2023510199A (pt)
KR (1) KR20220137007A (pt)
CN (1) CN115151258A (pt)
AU (1) AU2020416715A1 (pt)
BR (1) BR112022013143A2 (pt)
CA (1) CA3166571A1 (pt)
MX (1) MX2022008216A (pt)
WO (1) WO2021138079A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115087461A (zh) * 2019-12-20 2022-09-20 默沙东有限责任公司 使用pd-1拮抗剂、ilt4拮抗剂和化学治疗剂的组合治疗癌症的方法
WO2023077521A1 (en) * 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Anti-ilt4 and anti-pd-1 bispecific constructs

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160093012A (ko) * 2013-11-05 2016-08-05 코그네이트 바이오서비시즈, 인코포레이티드 암 치료를 위한 체크포인트 억제제 및 치료제의 배합물
CN112263677A (zh) * 2015-02-26 2021-01-26 默克专利股份公司 用于治疗癌症的pd-1/pd-l1抑制剂
TWI796329B (zh) * 2017-04-07 2023-03-21 美商默沙東有限責任公司 抗－ilt4抗體及抗原結合片段

Also Published As

Publication number Publication date
AU2020416715A1 (en) 2022-08-11
EP4084794A1 (en) 2022-11-09
KR20220137007A (ko) 2022-10-11
WO2021138079A1 (en) 2021-07-08
US20230058779A1 (en) 2023-02-23
CN115151258A (zh) 2022-10-04
JP2023510199A (ja) 2023-03-13
MX2022008216A (es) 2022-08-04
CA3166571A1 (en) 2021-07-08
EP4084794A4 (en) 2023-10-25

Similar Documents

Publication Publication Date Title
BR112022019557A2 (pt) Inibidores de replicação de norovírus e coronavírus
BR112022026899A2 (pt) Composto representado pela fórmula (i) ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método de tratamento ou prevenção de uma infecção por vírus, método de inibição da protease 3c viral ou protease 3cl viral em um mamífero e método de tratamento de um distúrbio respiratório
BR112022013143A2 (pt) Tratamento de combinação contra câncer usando um antagonista de pd-1, um antagonista de ilt4 e lenvatinibe ou sais dos mesmos
BR112014028633A8 (pt) tratamento de amd usando sflt-1 de aav
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
BR112015020787A2 (pt) inibidores quinazolínicos de formas mutantes ativantes do receptor do fator de crescimento epidérmico
DOP2021000198A (es) Compuestos y su uso en el tratamiento del cáncer
BR112018070536A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
CL2023000881A1 (es) Compuestos y su uso en el tratamiento del cáncer
BR112018015718A2 (pt) utilização de estimuladores de sgc para o tratamento de esteato-hepatite não alcoólica (nash)
BR112014023423A2 (pt) terapia de combinação
BR112013020586A2 (pt) Uso de células derivadas de tecido do cordão umbilical
DE602006017728D1 (de) Krebsbehandlung mittels fts und 2-deoxyglucose
BR112018070514A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
BR112021025764A2 (pt) Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo
BR112019022307A2 (pt) Derivados da pirrolopirimidina úteis como inibidores de replicação de vírus da influenza.
BR112022017189A2 (pt) Métodos de tratamento de glomeruloesclerose segmentar focal dependente de apol-1
BR112015002390A2 (pt) compostos
BR112015030623A2 (pt) agentes citotóxicos para o tratamento de câncer
BR112019002945A2 (pt) terapia de combinação para o tratamento de câncer pancreático
BR112023002295A2 (pt) Terapia de combinação
BR112021023347A2 (pt) Compostos de pirrolidina
WO2021262562A3 (en) Methods for treating cancer or von-hippel lindau disease using a combination of a pd-1 antagonist, a hif-2 alpha inhibitor, and lenvatinib or a pharmaceutically acceptable salt thereof
BR112019008698A2 (pt) método para tratar câncer num sujeito que precisa do mesmo e composição farmacêutica
BR112022019338A2 (pt) Tratamento preventivo de enxaqueca

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]